APOLLO HOSPITALS ENTER. L vs Q-LINE BIOTECH LIMITED

A side-by-side comparison of APOLLO HOSPITALS ENTER. L (APOLLOHOSP) and Q-LINE BIOTECH LIMITED (QLINE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

APOLLO HOSPITALS ENTER. L vs Q-LINE BIOTECH LIMITED are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.

  • Valuation22
  • Profitability04
  • Growth11
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

64.06
P/E ratio
18.55
12.55
P/B ratio
2.52
0.23%
Dividend yield
0.00%
₹135.04
EPS
₹34.24

Profitability

QLINE takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

22.10%
Return on equity
25.90%
18.00%
Return on capital
22.00%
15.00%
EBITDA margin
29.00%
7.94%
Net margin
16.37%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
23.18%
33.39%
Profit CAGR (3Y)
20.51%

Size & financial health

APOLLOHOSP takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.24L Cr
Market cap
₹1,245 Cr
₹25,228 Cr
Revenue
₹342 Cr
₹2,003 Cr
Net profit
₹56 Cr
0.32
Debt / equity
0.75
APOLLO HOSPITALS ENTER. L
  • + ["Company has delivered good profit growth of 76.2% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
  • ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
Q-LINE BIOTECH LIMITED
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%"]
  • ["Debtor days have increased from 92.7 to 134 days."]
APOLLO HOSPITALS ENTER. L full analysis Q-LINE BIOTECH LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.